Mastering CML management: Beyond Initial Response

Date and Time: 27 May 2026, 12:00-13:00 
Format: Virtual webinar (MS Teams) with live Q&A  
Invited lecturer: Professor Jane F. Apperley Department of Haematology at the Imperial College London, Clinical Haematology at the Imperial College Healthcare NHS Trust, London  
Moderation: Dr. Lovisa Vennström, Sahlgrenska University Hospital, Gothenburg

On behalf of Novartis, we are pleased to invite you to a virtual webinar with expert perspectives from Prof Jane F. Apperley.  

This session with Prof Jane Apperley addresses the clinical realities of sustained TKI therapy: navigating resistance mechanisms, managing treatment-limiting side effects, balancing efficacy with quality of life, and implementing patient-centric strategies. 

Agenda

12.00: Welcome

12.05-12.45: Mastering CML management: Beyond Initial Response, Prof. Jane. F Apperley:

• Low/intermediate -risk CML – balancing efficacy, tolerability and patient expectations

• High-risk CML patient management approaches – can early transplantation benefit high-risk patients in challenging resistant cases?

12.45-13.00: Q&A. Input from audience. Moderation by Dr. Lovisa Vennström 

13.00: Close

Warm welcome!

Andrea Villablanca, PhD

Medical Lead 
Mobile: +46709590193 

Participants are responsible for securing the head of clinic approval for participation. Participation in the meeting is free of charge. Novartis will pay, in accordance with LER, for meals, any venue costs and speaker fees within the framework of the meeting.

Få svar på dina frågor